These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25880391)

  • 1. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
    Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
    Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.
    Preuner S; Mitterbauer G; Mannhalter C; Herndlhofer S; Sperr WR; Valent P; Lion T
    Eur J Cancer; 2012 Jan; 48(2):233-6. PubMed ID: 21955823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors.
    Ma W; Giles F; Zhang X; Wang X; Zhang Z; Lee TS; Yeh CH; Albitar M
    Int J Lab Hematol; 2011 Jun; 33(3):326-31. PubMed ID: 21266020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
    Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
    Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
    Szankasi P; Schumacher JA; Kelley TW
    Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of chronic myeloid leukemia: present and future.
    Yeung CC; Egan D; Radich JP
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
    Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
    Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y
    Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
    J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
    Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
    El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
    PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
    Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.